Behavioral Complications of Drug Treatment of Parkinson's Disease
Identifieur interne : 002720 ( Main/Exploration ); précédent : 002719; suivant : 002721Behavioral Complications of Drug Treatment of Parkinson's Disease
Auteurs : Jeffrey L. Cummings [États-Unis]Source :
- Journal of the American Geriatrics Society [ 0002-8614 ] ; 1991-07.
Abstract
A variety of neuropharmacologic agents, including anticholinergic drugs, amantadine hydrochloride, levodopa, selegiline, bromocriptine, and pergolide, are now available for the treatment of Parkinson's disease. Of patients treated with dopaminergic agents, 30% develop visual hallucinations, 10% exhibit delusions, 10% have euphoria, 1% have mania, 10% to 15% experience increased anxiety, 15% have confusional periods, and a few exhibit altered sexual behavior. Anticholinergic drugs have a greater tendency to produce confusional states than dopaminergic compounds. Elderly patients and those with underlying dementia are most likely to have untoward side effects with anti‐parkinsonism treatment. Dosage reduction is the optimum management strategy, although anti‐psychotic agents may be necessary in patients with delusions, and lithium may help control drug‐induced mania. Dopaminergic agents share the property of stimulation of D2 dopamine receptors, and this action may play an essential role in mediating their neuropsychiatric effects.
Url:
DOI: 10.1111/j.1532-5415.1991.tb03627.x
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Behavioral Complications of Drug Treatment of Parkinson's Disease</title><author><name sortKey="Cummings, Jeffrey L" sort="Cummings, Jeffrey L" uniqKey="Cummings J" first="Jeffrey L." last="Cummings">Jeffrey L. Cummings</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7F7176FF61C7B1464443760C842A6C640E5D3C0E</idno><date when="1991" year="1991">1991</date><idno type="doi">10.1111/j.1532-5415.1991.tb03627.x</idno><idno type="url">https://api.istex.fr/document/7F7176FF61C7B1464443760C842A6C640E5D3C0E/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000510</idno><idno type="wicri:Area/Main/Curation">000441</idno><idno type="wicri:Area/Main/Exploration">002720</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Behavioral Complications of Drug Treatment of Parkinson's Disease</title><author><name sortKey="Cummings, Jeffrey L" sort="Cummings, Jeffrey L" uniqKey="Cummings J" first="Jeffrey L." last="Cummings">Jeffrey L. Cummings</name><affiliation wicri:level="2"><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Departments of Neurology and Psychiatry and Behavioral Sciences, UCLA School of Medicine, Los Angeles</wicri:cityArea></affiliation><affiliation wicri:level="2"><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Behavioral Neuroscience Section, Psychiatry Service, West Los Angeles Veterans Affairs Medical Center, Los Angeles</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of the American Geriatrics Society</title><idno type="ISSN">0002-8614</idno><idno type="eISSN">1532-5415</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1991-07">1991-07</date><biblScope unit="volume">39</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="708">708</biblScope><biblScope unit="page" to="716">716</biblScope></imprint><idno type="ISSN">0002-8614</idno></series><idno type="istex">7F7176FF61C7B1464443760C842A6C640E5D3C0E</idno><idno type="DOI">10.1111/j.1532-5415.1991.tb03627.x</idno><idno type="ArticleID">JGS3627</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0002-8614</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A variety of neuropharmacologic agents, including anticholinergic drugs, amantadine hydrochloride, levodopa, selegiline, bromocriptine, and pergolide, are now available for the treatment of Parkinson's disease. Of patients treated with dopaminergic agents, 30% develop visual hallucinations, 10% exhibit delusions, 10% have euphoria, 1% have mania, 10% to 15% experience increased anxiety, 15% have confusional periods, and a few exhibit altered sexual behavior. Anticholinergic drugs have a greater tendency to produce confusional states than dopaminergic compounds. Elderly patients and those with underlying dementia are most likely to have untoward side effects with anti‐parkinsonism treatment. Dosage reduction is the optimum management strategy, although anti‐psychotic agents may be necessary in patients with delusions, and lithium may help control drug‐induced mania. Dopaminergic agents share the property of stimulation of D2 dopamine receptors, and this action may play an essential role in mediating their neuropsychiatric effects.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li></region></list><tree><country name="États-Unis"><region name="Californie"><name sortKey="Cummings, Jeffrey L" sort="Cummings, Jeffrey L" uniqKey="Cummings J" first="Jeffrey L." last="Cummings">Jeffrey L. Cummings</name></region><name sortKey="Cummings, Jeffrey L" sort="Cummings, Jeffrey L" uniqKey="Cummings J" first="Jeffrey L." last="Cummings">Jeffrey L. Cummings</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002720 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002720 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:7F7176FF61C7B1464443760C842A6C640E5D3C0E
|texte= Behavioral Complications of Drug Treatment of Parkinson's Disease
}}
| This area was generated with Dilib version V0.6.23. |  |